NEU²

new drugs
against
neurological diseases

 
 

press release

Epomedics GmbH joins NEU²


Kiel/Hamburg, June 2012: Bionamics GmbH, the coordinator of the NEU² consortium is pleased to announce that Epomedics GmbH (Göttingen) joined the NEU² program with a project addressing the development of innovative biological therapeutics for the chronic progressive forms of multiple sclerosis (MS). The new project is scheduled for three years and is funded proportionally by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.

Epomedics’ current activities focus on the preclinical development of a brain specific variant of Erythropoietin (EPO) which is believed to display beneficial neuroprotective effects in certain CNS diseases including MS. If successful, this undertaking will provide the basis for the instant evaluation of novel EPO derived drug candidates in subsequent clinical studies. In chronic progressive MS as well as in other CNS diseases characterized by neurodegenerative pathology, neuroprotective and neuroregenerative therapeutic approaches are addressing a broad field with substantial unmet needs.

Dr. Herbert Stadler, CEO of Epomedics GmbH: “We are pleased to join the NEU² consortium and hope that the further investigations of our brain specific EPO variant with its neuroprotective and neuroregenerative properties as a potential therapeutic for MS will be a valuable contribution to the treatment of this disease.”

Dr. Timm Jessen, CEO of Bionamics GmbH and founder of NEU², about the expansion of the NEU² consortium: “Epomedics constitutes an attractive new partner for the consortium based on its project, its expertise and its close interaction both with the scientific and biotech community and we are glad we could win them for us.”

About Epomedics GmbH

Epomedics is a privately held German biopharmaceutical company dedicated to the development of EPO and variants thereof for the treatment of CNS diseases. Epomedics holds key patents for use of EPO in stroke, schizophrenia and multiple sclerosis and also for recently discovered EPO variants. (http://www.epomedics.com)

About NEU²

The NEU² consortium, including, amongst others, Merck KGaA, Evotec AG, European ScreeningPort GmbH, Bionamics GmbH, and the University Medical Center Hamburg-Eppendorf was successful in the nationwide “BioPharma” strategy competition of The Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung – BMBF). This initiative aims to promote innovative partnerships between academic institutions, biotechnology and pharmaceutical companies in order to strengthen the pharmaceutical value chain in Germany. The NEU² consortium focuses on the development of novel therapies against neurological diseases with a specific focus on multiple sclerosis. The NEU² consortium is coordinated by Bionamics GmbH, an independent project management company and founder of NEU².

Contact

Dr. Timm-H. Jessen
Gottorfstr. 3
24837 Schleswig
Tel: +49 4621 9787376
Fax: +49 4621 9787375
E-Mail: jessen@bionamics.de

Archives

Sponsored by:

and supported by: